This bill reenacts and amends Washington’s pharmacy statute (RCW 18.64.011), adds a new section to chapter 18.64 RCW, and amends RCW 69.41.030 to expand pharmacists’ legal scope of practice. It expressly expands the statutory definition of the practice of pharmacy to include limited diagnosing (as referenced to section 3 of the act) and authorizes pharmacists to prescribe or order drugs and devices as allowed by the chapter and commission rules. The Pharmacy Quality Assurance Commission is authorized to adopt rules to administer and implement the act. Beginning December 1, 2027, the bill permits pharmacists to prescribe a specified list of items and categories, including immunizations; opioid antagonists and medications to treat addiction; epinephrine autoinjectors; antihistamine agents; tobacco cessation products; medications to prevent HIV; tuberculin purified protein derivative products; hormonal contraception; medications to treat or prevent travel-related diseases; and certain other drugs, drug categories, or devices limited to conditions that meet specified criteria (for example, conditions that do not require a new diagnosis, minor and generally self-limiting conditions, conditions guided by CLIA-waived tests or devices, or prescriptions in team-based practices with a shared medical record). The act also amends the statute on unlawful sale, delivery, possession, or use of legend drugs (RCW 69.41.030) to restate that legend drugs are unlawful except upon the order or prescription of specified licensed practitioners and to set out exceptions and enforcement provisions. The bill reenacts and expands numerous statutory definitions used throughout chapter 18.64 RCW (for example, definitions of pharmacist, pharmacy, dispensing, administering, legend drugs, and practice of pharmacy). It affects the Pharmacy Quality Assurance Commission, the Department of Health (including the secretary), pharmacists and pharmacies, various practitioner boards and entities referenced in existing statutes, and certain health care entities. Important text is missing from the provided excerpts: the full language of section 3 (which governs the limited diagnosing authority), the specific amendments to RCW 69.41.030, the expiration date noted in the bill header, and a fragmentary definition that begins mid-sentence; those provisions are therefore uncertain from the materials supplied.

If enacted, pharmacists would be able beginning December 1, 2027 to directly prescribe a specified list of preventive and short‑term treatments—things like immunizations, opioid antagonists and addiction treatments, epinephrine autoinjectors, antihistamines, tobacco cessation products, HIV prevention medications, tuberculin PPD, hormonal contraception, travel medicines, and certain other items for minor conditions that meet set criteria. This will likely make those services faster and more available, especially in rural and underserved areas, because patients can get these medicines and devices from pharmacies without first seeing a physician or other traditional prescriber. The groups most affected are pharmacists and licensed pharmacies, which will take on new prescribing responsibilities and related training, equipment (for any CLIA‑waived testing), and potential oversight or compliance costs as the Pharmacy Quality Assurance Commission writes implementing rules. Primary care and other prescribers may see fewer routine visits for these items. There is uncertainty about some operational limits because the bill’s full diagnostic provisions (section 3), the exact language changing possession/prescription enforcement, and the bill’s stated expiration date are not included in the provided text, so how tightly the new prescribing authority will be regulated or time-limited is unclear.